Loading...
•
Jun 30, 2024
Evolus Q2 2024 Earnings Report
Achieved quarterly profitability for the first time, driven by record revenue and strong execution.
Key Takeaways
Evolus reported a 36% increase in total net revenue for Q2 2024, reaching $66.9 million. The company achieved its first ever quarter of profitability with positive non-GAAP operating income of $1.1 million. Full-year 2024 net revenue guidance was raised to $260 million to $270 million.
Total net revenue for Q2 2024 increased 36% year-over-year to $66.9 million.
GAAP operating loss improved to $7.7 million.
Achieved positive non-GAAP operating income of $1.1 million for Q2 2024.
Full-year 2024 net revenue guidance raised to $260 million to $270 million.
Revenue by Segment
Forward Guidance
Evolus expects full year 2024 net revenues between $260 million and $270 million, representing 34% year-over-year growth at the top end. The company anticipates a full-year adjusted gross profit margin between 68% and 71% and expects full-year non-GAAP operating expenses between $185 million and $190 million. Evolus expects to achieve positive non-GAAP operating income on a consolidated basis for the fourth quarter of 2024 and for the full year 2025.
Positive Outlook
- Full-year 2024 net revenue expected to be between $260 million and $270 million, representing 34% year-over-year growth at the top end.
- Adjusted gross profit margin for the full year 2024 expected to be between 68% and 71%.
- Full-year non-GAAP operating expenses expected to be between $185 million and $190 million.
- Positive non-GAAP operating income expected for Q4 2024 and full year 2025.
- Expansion into additional countries with Nuceiva®, including launch in Australia in Q3 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...